Skip to main content

Market Overview

The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

The Daily Biotech Pulse: Endologix's Q3 Sales, Obseva's Positive Trial Results, Kala To Offer Shares

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Biotech stocks hitting 52-week highs on Oct. 1)

  • Boston Scientific Corporation (NYSE: BSX)
  • Eli Lilly And Co (NYSE: LLY)
  • Masimo Corporation (NASDAQ: MASI)
  • Merck & Co., Inc. (NYSE: MRK)
  • Merit Medical Systems, Inc. (NASDAQ: MMSI)
  • Trevena Inc (NASDAQ: TRVN)
  • Urovant Sciences Ltd. (Nasdaq: UROV)

Down In The Dumps

(Biotech stocks hitting 52-week lows on Oct. 1)

  • Arvinas Inc (NASDAQ: ARVN)
  • Avrobio Inc (NASDAQ: AVRO)
  • Genprex Inc (NASDAQ: GNPX)
  • Gritstone Oncology, Inc. (NASDAQ: GRTS)
  • GTx, Inc. (NASDAQ: GTXI)
  • Kala Pharmaceuticals Inc (NASDAQ: KALA)
  • La Jolla Pharmaceutical Company (NASDAQ: LJPC)
  • Magenta Therapeutics Inc (NASDAQ: MGTA)
  • OptiNose Inc (NASDAQ: OPTN)
  • Sonoma Pharmaceuticals Inc (NASDAQ: SNOA)
  • Titan Pharmaceuticals, Inc. (NASDAQ: TTNP)
  • Vital Therapies Inc (NASDAQ: VTL)

See Also: Attention Biotech Investors: Mark Your Calendar For These October PDUFA Dates

Stocks In Focus

Endologix Expects Q3 Revenues Above Consensus; Raises Low-End Of FY18 Revenue Guidance

Endologix, Inc. (NASDAQ: ELGX) announced preliminary third-quarter results, expecting revenues in the range of $34.3 million to $34.7 million, ahead of the $31.13 million consensus estimate. Citing the current business trends, the company raised the low-end of its 2018 revenue guidance to $150 million from $145 million, while maintaining the high-end at $155 million.

The stock soared 37.21 percent to $2.36 in after-hours trading.

Novartis Out-Licenses 3 Anti-Infectives

Novartis AG (NYSE: NVS) said it licensed three novel anti-infective drug candidates to Boston Pharma. These pipeline assets have the potential to treat antibiotic-resistant Gram-negative infections.

Obseva Reports Additional Positive Data For Nolasiban

Obseva SA (NASDAQ: OBSV) released additional positive Phase 3 data from the IMPLANT 2 trial of its oral, oxytocin receptor antagonist Nolasiban in patients undergoing IVF procedures. The data showed that the candidate significantly increased live birth rate following IVF treatment.

An additional Phase 3 trial is set to begin prior to the end of 2018 and is expected to generate primary endpoint, 10-week ongoing pregnancy data, in about 12 months, allowing for a planned MAA submission in Europe by the end of 2019.


Epizyme Inc (NASDAQ: EPZM) priced its underwritten public offering of 8.33 million shares of its common stock at $9 per share, a discount to Tuesday's closing price of $9.71. All the shares are to be sold by the company. The company expects gross proceeds of $75 million from the offering.

The stock shed 7.31 percent to $9 in after-hours trading.

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) priced its previously announced offering of 1.90 million ADSs, representing 22.8 million ordinary shares, at a price of $158 per ADS. The company expects to raise gross proceeds of about $300 million from the offering.

Kala Pharma said it commenced an underwritten public offering of 7.50 million shares. Separately, the company said it closed its $110 million credit facility with funds managed by Athyrium Capital Management.

The stock fell 9.48 percent to $8.40 in after-hours trading.


Related Articles (IBB + NVS)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Offerings Top Stories Trading Ideas Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at